New heart pump could replace ECMO in risky angioplasty
NCT ID NCT07622446
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether a new device called OmniHeart 4.0 can safely support the heart during high-risk angioplasty, compared to the standard ECMO machine. About 254 patients will be randomly assigned to receive either the OmniHeart or ECMO. Researchers will track major heart and brain complications within 30 days to see if the new device is as effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OmniHeart 4.0 percutaneous ventricular assist device
What this could lead to
If successful, this device could offer a less invasive alternative to ECMO for supporting the heart during high-risk angioplasty, potentially reducing complications.
What could go wrong
This is an early-stage, non-inferiority trial with 254 participants, so results may not apply to all patients. The device may not perform as well as ECMO, and risks include bleeding, infection, or device failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK PCI are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Dynaheart Medtech Co., Ltd
Shanghai, China
-
The Second Affiliated Hospital of Harbin Medical University
Jilin City, China